Xerostomia

Salivary Gland Disorders

Volumn , Issue , 2007, Pages 185-199

  Chambers, Mark S ^a   Artopoulou, Ioli Ioanna ^b   Garden, Adam S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886729121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-47072-4_11     Document Type: Chapter

References (95)

1. Chambers MS (2004) Sjögren's Disease. ORL Head Neck Nurs 22:22-30
2. Dawes C (1987) Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66(Spec Issue):648-653
3. Percival RS, Challacombe SJ, Marsh PD (1994) Flow rates of resting whole and stimulated parotid saliva in relation to age and gender. J Dent Res 73:1416-1420
4. Fox PC, Eversole R (2001) Diseases of the salivary glands. In: Silverman S, Eversole LR, & Truelove E (Eds.) Essentials of oral medicine (pp. 260-276). Hamilton: BC Decker
5. Mercadante S, Calderone L, Villari P (2000) The use of pilocarpine in opioid-induced xerostomia. Palliat Med 14:529-531
6. Chambers MS, Toth BB, Martin JW, et al. (1995) Oral and dental management of the cancer patient: Prevention and treatment of complications. Support Care Cancer 3:168-175
7. Peterson DE (2000) Oral problems in supportive care: No longer an orphan topic? Support Care Cancer 8:347-348
8. Chambers MS (2003) Clinical commentary on prophylactic treatment of radiation-induced xerostomia. Arch Otolaryngol Head Neck Surg 129:251-252
9. Davies AN, Singer J (1994) A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 108:663-665
10. Narhi TO (1994) Prevalence of subjective feelings of dry mouth in the elderly. J Dent Res 73:20-25
11. Schiodt M (1992) HIV-associated salivary gland disease: A review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 73:164-167
12. Sreebny LM, Valdini A, Yu A (1989) Xerostomia. Part II: Relationship to nonoral symptoms, drugs, and diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 68:419-427
13. Chambers MS, Garden AS, Kies MS, et al. (2004) Radiation-induced xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head Neck 26:796-807
14. Shaha AR, Patel S, Shasha D, Harrison LB (2001) Head and neck cancer. In: Lenhard RE Jr., Osteen RT, Gansler T, editors. Clinical oncology. Atlanta, Ga: American Cancer Society; pp 297-330
15. Criswell MA, Sinha CK (2001) Hyperthermic, supersaturated humidification in the treatment of xerostomia. Laryngoscope 111:992-996
16. Seikaly H, Jha N, McGaw T, et al. (2001) Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 111:347-352
17. Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22:820-825
18. Kao CH, Tsai SC, Sun SS (2001) Scintigraphic evidence of poor salivary function in type 2 diabetes. Diabetes Care 24:952-953
19. Nicolatou-Galitis O, Kitra V, Vliet-Constantinidou C, et al. (2001) The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med 30:148-153
20. Kies MS, Haraf DJ, Rosen F, et al. (2001) Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19:1961-1969
21. Bergdahl M, Bergdahl J (2000) Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 79:1652-1658
22. Malone-Lee JG, Walsh JB, Maugourd MF (2001) Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 49:700-705
23. California Dental Hygienists Association. Xerostomia: drymouth. Available at: http://www.cdha.org/articles/drymouth. htm. Accessed February 7, 2003
24. Sjogren R, Nordstrom G (2000) Oral health status of psychiatric patients. J Clin Nurs 9:632-638
25. Nagler RM, Gez E, Rubinov R, et al. (2001) The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma. Arch Oral Biol 46:487-493
26. Logemann JA, Smith CH, Pauloski BR, et al. (2001) Effects of xerostomia on perception and performance of swallow function. Head Neck 23:317-321
27. Eisbruch A, Kim HM, Terrell JE, et al. (2001) Xerostomia and its predictors following parotidsparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:695-704
28. Jellema AP, Langendijk H, Bergenhenegouwen L, et al. (2001) The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 59:157-160
29. Leek H, Albertsson M (2002) Pilocarpine treatment of xerostomia in head and neck patients. Micron 33:153-155
30. Reddy SP, Leman CR, Marks JE, et al. (2001) Parotid sparing irradiation for cancer of the oral cavity: maintenance of oral nutrition and body weight by preserving parotid function. Am J Clin Oncol 24:341-346
31. Berger AM, Kilroy TJ (1998) Oral complications of cancer therapy. In: Berger AM, Portenoy RK, Weissman DE, editors. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven Publishers; pp 223-236
32. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346
33. Trotti A, Colevas D, Setser A, et al. (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181
34. Common Terminology Criteria for Adverse Events v3.0 (CTCAE): http://ctep.cancer.gov/forms/CTCAEv3.pdf; published December 12, 2003
35. Chambers MS, Keene HJ, Toth BB, et al. (2002) Mutans Streptococci in xerostomic cancer patients after pilocarpine therapy. J Dent Res 81, Special Issue A ( IADR/AADR Abstract 3609); 443
36. Slavkin HC, Baum BJ (2000) Relationship of dental and oral pathology to systemic illness. JAMA 284:1215-1217
37. Spielman AI (1990) Interaction of saliva and taste. J Dent Res 69:838-843
38. Hughes PJ, Scott PM, Kew J, et al. (2000) Dysphagia in treated nasopharyngeal cancer. Head Neck 22:393-397
39. Harrison LB, Zelefsky MJ, Pfister DG, et al. (1997) Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 19:169-175
40. Epstein JB, Robertson M, Emerton S, et al. (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23:389-398
41. Schubert MM, Peterson DE, Lloid ME (1999) Oral complications. In: Thomas ED, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed. Malden, Ma: Blackwell Science Inc.; pp 751-763
42. Hensley ML, Schuchter LM, Lindley C, et al. (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355
43. Lindegaard JC, Grau C (2000) Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57:113-118
44. Brizel DM, Wasserman TH, Henke M, et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345
45. Spiegel JH, Deschler DG, Cheney ML (2001) Microvascular transplantation and replantation of the rabbit submandibular gland. Arch Otolaryngol Head Neck Surg 127:991-996
46. Spiegel JH, Zhang F, Levin DE, et al. (2000) Microvascular transplantation of the rat submandibular gland. Plast Reconstr Surg 106:1326-1335
47. Greer JE, Eltorky M, Robbins KT (2000) A feasibility study of salivary gland autograft transplantation for xerostomia. Head Neck 22:241-246
48. Nagler RM, Baum BJ (2003) Treatment reduces the severity of xerostomia following radiation therapy for oral cavity cancer. Arch Otolaryngol Head Neck Surg 129:245-251
49. Delporte C, O'Connell BC, He X, et al. (1997) Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA 94:3268-3273
50. Epperly MW, Gretton JA, DeFilippi SJ, et al. (2001) Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat Res 155:2-14
51. Epperly MW, DeFelippi SJ, Sikora CA, et al. (2000) Intratracheal injection A manganese superoxide dismutase (Mn-SOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7:1011-1018
52. LeVeque FG, Montgomery M, Potter D, et al. (1993) A multicenter, randomized, double-blind, placebo-controlled, dosetitration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124-1131
53. Fox PC, van der Ven PF, Baum BJ, et al. (1986) Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 61:243-248
54. Chambers MS, Toth BB, Payne R, et al. (1997) Mutans streptococci and salivary flow rates in cancer patients attending a pain clinic [abstract]. J Dent Res 76:358. Abstract 2755
55. Chambers M, Martin C, Toth B, et al. (1997) Assessment of functional improvement in cancer patients with oral pilocarpine as treatment for analgesia-induced xerostomia [abstract]. Support Care Cancer 5:164. Abstract 45
56. Chambers M, Toth B, Martin C, et al. (1997) Assessment of salivary flow improvement in cancer patients with oral pilocarpine as treatment for analgesia-induced xerostomia [abstract]. Proc Am Soc Clin Oncol 16:50a. Abstract 174
57. Scarantino CW, Leveque F, Scott C, et al. (2001) A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients [abstract]. Int J Radiat Oncol Biol Phys 51(suppl 1):85-86. Abstract 152
58. Warde P, Aslanidis J, Kroll B, et al. (2001) A phase III placebo controlled trial of oral pilocarpine in patients undergoing radiation therapy for head and neck cancer [abstract]. Int J Radiat Oncol Biol Phys 51(suppl 1):86. Abstract 153
59. Cancer Care Ontario Practice Guideline Initiative. Hodson DI, Haines T, Berry M, et al. and the Head and Neck Cancer Disease Site Group. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients (Practice Guideline Report No. 5-5). Available at: http:// www.ccopebc.ca/ guidelines/head/cpg5-5f.html. Accessed February 7, 2003
60. Johnson JT, Ferretti GA, Nethery WJ, et al. (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390-395
61. Greenspan D, Daniels TE (1987) Effectiveness of pilocarpine in postradiation xerostomia. Cancer 59:1123-1125
62. Schuller DE, Stevens P, Clausen KP, et al. (1989) Treatment of radiation side effects with oral pilocarpine. J Surg Oncol 42:272-276
63. Davies AN, Singer J (1994) A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 108:663-665
64. Jacobs CD, van der Pas M (1996) A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntingt) 10(suppl):16-20
65. Wiseman LR, Faulds D (1995) Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 49:143-155
66. Atkinson JC, Baum BJ (2001) Salivary enhancement: current status and future therapies. J Dent Educ 65:1096-1101
67. Al-Hashimi I (2001) The management of Sjögren's syndrome in dental practice. J Am Dent Assoc 132:1409-1417
68. Iga Y, Arisawa H, Ogane N, et al. (1998) (F)-cis-2-methylspiro[ 1,3-oxathiolane-5,3(-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 78:373-380
69. Petrone D, Condemi JJ, Fife R, et al. (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46:748-754
70. Evoxac Capsules (cevimeline hydrochloride). In: Physician's desk reference. 55th ed. Montvale, NJ: Medical Economics Co; 2001:1110-1112
71. Olsson H, Spak CJ, Axell T (1991) The effect of a chewing gum on salivary secretion, oral mucosal friction, and the feeling of dry mouth in xerostomic patients. Acta Odontol Scand 49:273-279
72. Chambers MS, Garden AS, Rosenthal DI, et al. (2005) Intensity-modulated radiotherapy: Is xerostomia still prevalent? Curr Oncol Rep 7:131-136
73. Eisbruch A, Foote RL, O'Sullivan B, et al. (2002) Intensitymodulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2:238-249
74. Ozyigit G, Yang T, Chao KS (2004) Intensity-modulated radiation therapy for head and neck cancer. Curr Treat Options Oncol 5:3-9
75. Eisbruch A, Dawson LA, Kim HM, et al. (1999) Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg 53:271-275
76. Garden AS, Morrison WH, Rosenthal DI, et al. (2004) Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 14:103-109
77. Chao KS (2002) Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 12(Suppl 1):20-25
78. Dreizen S, Brown LR, Daly TE, et al. (1977) Prevention of xerostomia related dental caries in irradiated cancer patients. J Dent Res 56:99-104
79. Emami B, Lyman J, Brown A, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122
80. Leslie MD, Dische S (1991) Parotid gland function following accelerated and conventionally fractionated radiotherapy. Radiother Oncol 22:133-139
81. O'Sullivan B, Warde P, Grice B, et al. (2001) The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 51:332-343
82. Eisbruch A, Ship JA, Kim HM, et al. (2001) Partial irradiation of the parotid gland. Semin Radiat Oncol 11:234-239
83. Webb S (2001) IMRT: General considerations. In Intensitymodulated Radiation Therapy. Edited by Webb S. Philadelphia: Institute of Physics Publishing; pp 1-34
84. Henson BS, Inglehart MR, Eisbruch A, et al. (2001) Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotidsparing radiotherapy. Oral Oncol 37:84-93
85. Eisbruch A, Ten Haken RK, Kim HM, et al. (1999) Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577-587
86. Eisbruch A, Ship JA, Dawson LA, et al. (2003) Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 27:832-837
87. Lin A, Kim HM, Terrell JE, et al. (2003) Quality of life after parotid sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57:61-670
88. Chao KS, Deasy JO, Markman J, et al. (2001) A prospective study of salivary function sparing in patients with headand-neck cancers receiving intensity-modulated or threedimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 49:907-916
89. Chao KS, Majhail N, Huang CJ, et al. (2001) Intensitymodulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 61:275-280
90. Chao KS, Low DA, Perez CA, et al. (2000) Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 90:92-103
91. Chao KS, Ozyigit G, Blanco AI, et al. (2004) Intensitymodulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 59:43-50
92. Eisbruch A, Marsh LH, Dawson LA, et al. (2004) Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59:28-42
93. Astreinidou E, Dehnad H, Terhaard CH, et al. (2004) Level II lymph nodes and radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 58:124-131
94. Munter MW, Karger CP, Hoffner SG, et al. (2004) Evaluation of salivary gland function after treatment of head-andneck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 58:175-184
95. Eisbruch A (2002) Clinical aspects of IMRT for head-andneck cancer. Med Dosim 27:99-104